The company says its renowned ImmunoINSIGHTS platform is recognized for its prowess in antibody marker discovery and will now be used to unearth novel biomarkers associated with ageing and age-related conditions.
It says this will underscore Oncimmune’s unwavering commitment to confronting the multifaceted challenges posed by aging, where it aims to play a key role in propelling precision medicine forward.
With an eye on accelerating therapeutic breakthroughs, Oncimmune says it has already forged collaborations with top-tier drug discovery entities and garnered interest from global pharmaceutical giants seeking to leverage its technology in this burgeoning domain.
The company explained that as longevity becomes increasingly prevalent, the immune system undergoes a metamorphosis termed immunosenescence, a phenomenon implicated in the onset of age-related ailments. A notable contributor to such diseases is the surge in autoantibody production, antibodies erroneously targeting the body’s own tissues. These autoantibodies are implicated in a spectrum of autoimmune disorders, including rheumatoid arthritis, lupus, and autoimmune thyroid diseases, which exhibit heightened prevalence with advancing age. Furthermore, autoantibodies exacerbate chronic inflammation, a hallmark feature of numerous age-related maladies such as cardiovascular diseases, and neurodegenerative disorders including Alzheimer’s, Parkinson’s, and diabetes.
Age-related conditions
Oncimmune’s pioneering strides in these therapeutic arenas have already yielded significant discoveries, including biomarkers facilitating early rheumatoid arthritis treatment and systemic sclerosis diagnosis. Now, the company is setting its sights on unraveling the intricate interplay between autoantibodies and age-related conditions, with a keen focus on identifying and validating novel biomarkers. These biomarkers hold the promise of enabling targeted interventions and personalized medicine tailored to individual patient profiles.
With its cutting-edge technology, Oncimmune says it aims to bolster clinical trials by facilitating the recruitment of patients grappling with early-onset age-related conditions, while concurrently monitoring disease progression and intervention responses. This concerted effort is poised to unearth fresh therapeutic targets, potentially heralding a new era of breakthrough treatments for age-related ailments.
Martin Gouldstone, CEO of Oncimmune, is slated to elucidate how ImmunoINSIGHTS can fortify clinical trial endeavours at the upcoming Pioneer Presents event on Healthy Ageing, scheduled tomorrow (April 24th) at the Kent Science Park. Gouldstone expressed optimism regarding the transformative potential of ImmunoINSIGHTS in spearheading advancements in diagnosis and treatment modalities for age-related diseases while streamlining the clinical trial landscape to enhance efficiency and productivity.
Gouldstone said: “As aging-related diseases become more prevalent in society, we believe that our ImmunoINSIGHTS technology can be instrumental in finding better diagnosis and treatment solutions for these diseases while making clinical trials more efficient and productive. We are working closely with our partners in this area, and I look forward to discussing the topic with world-leading experts later this month.”
